OAB and Incontinence

The FDA previously approved the Ieva Digital Therapeutic System for the treatment of urinary incontinence and pelvic floor strengthening in women.

“Doing this study allows us to say, 'With repeat treatments, we're not seeing a greater risk of retention, and we're not seeing a greater risk of UTI,'" says David A. Ginsberg, MD.

"Spend a few extra minutes to learn about emotions and voiding in your patient," writes Gopal H. Badlani, MD.

"For patients who can maintain a functional implant in-situ, long-term patient satisfaction rates remain high," said Elodie Beels, MD.

"We believed that the drug would work as well in OAB wet as it did in OAB dry, so we're pleased to see that it was statistically significantly better than placebo at the 12-week point for looking at response to both metrics in both group," says David Staskin, MD.

"I think another good take-home message is the importance of the informed consent process," says Una Lee, MD.

"As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on," says Anne M. Suskind, MD, MS, FACS, FPMRS.

“Qmax at 1, 3, 6, 9, and 12 months and voiding volume at 3 months were significantly lower in the impaired group than in the preserved group. This suggests that preoperative lower bladder contractility was associated with prolonged deterioration of voiding function,” says Junya Hata, PhD.

“I think the surgeon voice is an important voice to be heard because there's not a lot of avenues for surgeons to be able to be honest and share all the things they've learned and all the things they've experienced with their patients,” says Una Lee, MD, FPMRS.

In this interview, Melissa R. Kaufman, MD, PhD, FACS, describes the promise of a regenerative approach to treating recurrent incontinence in women known as autologous muscle derived cells for urinary sphincter repair (AMDC-USR).

In an effort to destigmatize urinary incontinence, Jai Seth, MD, discusses why it is important to educate the general public about this medical condition so that it can be normalized rather than stigmatized.

As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on,” says Anne M. Suskind, MD, MS, FACS, FPMRS.

“One of the study findings that really stood out to me was that so many of the surgeons that we spoke to are…such strong advocates for their patients,” says Wai Lee, MD.

“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.

“The goals of [this phase of the] trial were to confirm system performance, to evaluate patient compliance, and to determine daily stimulation duration,” said Dr. Steven W. Siegel.

Daytime incontinence decreased in two-thirds of participants who performed core stability exercises.

“As health care professionals, we've got…an incredibly important role and responsibility with regards to increasing awareness and education, and then really trying to address the barriers and bring down the barriers,” says Jai Seth, MD.

“This is a successfully completed phase 3 trial in regenerative medicine in our field, and there's demonstrated safety and efficacy for women who have failed previous surgery, a very difficult group of patients for all of us,” says Michael B. Chancellor, MD.

Moderate physical activity and a greater time spent participating in moderate physical activity was associated with a decreased likelihood of stress, urge and mixed urinary incontinence in women.

“We found that in patients presenting with LUTS, there is an association between urinary incontinence and [worse] sexual function,” said study author Giuseppe Fallara, MD.

“It works on the bladder [and] it relieves the symptoms of people who have overactive bladder, but it doesn't do any adverse things to blood pressure or heart rate.” says Michael A. Weber, MD.

There was not a similar reduction in nocturnal voids among patients with a decrease in systolic blood pressure.

A decrease in urinary ATP levels following onabotulinumtoxinA (Botox) injections corresponded to clinical improvements in overactive bladder symptoms.

"Prior to this study, there was really no data on exactly how long it takes until Botox begins to take effect in the bladder," said Howard B. Goldman, MD.

The OAB symptoms, known as COVID-19–associated Cystitis, include increased urinary urgency, frequency, nocturia, and pain.